Professor Lisa Butler is a Program Lead and Group Leader at the South Australian Immunogenomics Cancer Institute (SAiGENCI) at the University of Adelaide. She holds a Ph.D. in cancer biology from the University of Adelaide with postdoctoral training in preclinical drug development at Memorial Sloan-Kettering Cancer Centre in New York. Prof Butler’s research focuses on androgen signalling and lipid metabolism in prostate cancer, and on biomarker discovery coupled to drug development. She has established translational research programs that leverage her unique preclinical models involving primary clinical samples, prostate biobanking and proof-of-concept clinical trials.